The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 09, 2021
Filed:
Nov. 22, 2016
Applicant:
Salk Institute for Biological Studies, La Jolla, CA (US);
Inventors:
Ronald M. Evans, La Jolla, CA (US);
Eiji Yoshihara, La Jolla, CA (US);
Michael R. Downes, La Jolla, CA (US);
Ruth T. Yu, La Jolla, CA (US);
Annette R. Atkins, La Jolla, CA (US);
Assignee:
SALK INSTITUTE FOR BIOLOGICAL STUDIES, La Jolla, CA (US);
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 35/39 (2015.01); C12N 5/071 (2010.01); C07K 14/705 (2006.01); C07K 14/72 (2006.01); A61K 48/00 (2006.01); A61K 35/12 (2015.01); A61K 35/35 (2015.01); A61K 35/51 (2015.01); A61K 35/545 (2015.01); C12N 15/85 (2006.01); C12N 15/86 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
A61K 35/39 (2013.01); A61K 35/12 (2013.01); A61K 35/35 (2013.01); A61K 35/51 (2013.01); A61K 35/545 (2013.01); A61K 48/00 (2013.01); C07K 14/70567 (2013.01); C07K 14/721 (2013.01); C12N 5/0676 (2013.01); C12N 15/85 (2013.01); C12N 15/86 (2013.01); A61K 38/00 (2013.01); C12N 2501/105 (2013.01); C12N 2501/115 (2013.01); C12N 2501/392 (2013.01); C12N 2501/415 (2013.01); C12N 2506/02 (2013.01); C12N 2510/00 (2013.01); C12N 2710/10032 (2013.01); C12N 2710/10043 (2013.01);
Abstract
The invention features compositions comprising in vitro generated beta cells capable of glucose-stimulated insulin secretion, methods of inducing beta cell maturation from embryonic or induced pluripotent stem cell-derived beta-like cells, and methods of using in vitro generated beta cells for the treatment of type 1 diabetes, type 2 diabetes, or a related disorder.